Beam Therapeutics Inc.

Healthcare · Biotechnology · United States

Last price 27.23 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.72B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylk...